Início
Mercados
Gráficos e ideias
Algo
Notícias
Market
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Heatmap
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
FATE
#3834
Fate Therapeutics, Inc.
1.2
9
USD
-3.73%
Setor:
Cuidados de saúde
Base:
USD
Moeda do lucro:
USD
Faixa diária
Faixa anual
Mudança diária
-3.73%
Mudança mensal
+10.26%
Mudança em 6 meses
-15.13%
Mudança anual
+14.16%
Fechamento anterior
1.3
4
Abrir
1.2
9
Bid
Ask
Mínimo
1.2
9
High
1.2
9
Volume
35
Mercados
Ações
Cuidados de saúde
FATE
Abrir gráfico completo
Financials
Visão geral
Relatórios
Estatísticas
Trimestral
Ano
Valor
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
TTM
Key stats
Total common shares outstanding
114.6 M
114.63 M
115.33 M
115.35 M
116.26 M
—
Valuation ratios
Enterprise value
153.03 M
45.65 M
87.92 M
104.72 M
67.62 M
305.92 M
Price to earnings ratio
-1.01
-0.53
-0.77
-0.95
-0.85
-3.11
Price to sales ratio
13.76
6.94
15.49
20.71
17.56
60.7
Price to cash flow ratio
-1.53
-0.75
-1.13
-1.34
-1.1
-4.32
Price to book ratio
0.59
0.07
0.11
0.13
0.56
0.87
Enterprise value to EBITDA ratio
-0.8
-0.25
-0.5
-0.65
-0.5
-1.9
Profitability ratios
Return on assets %
-0.12
-0.09
-0.09
-0.09
-0.1
-0.38
Return on equity %
-0.16
-0.13
-0.13
-0.14
-0.16
-0.55
Return on invested capital %
-125.44
—
—
—
-71.97
—
Gross margin %
100
100
100
100
100
400
Operating margin %
-3 319.78
-2 534.07
-1 938.54
-1 995.12
-2 536.23
-9 003.96
EBITDA margin %
-3 061.02
-2 329.47
-1 766.65
-1 809.76
-2 312.49
-8 218.37
Net margin %
-2 803.92
-2 309.45
-1 786.58
-1 852.38
-2 364.79
-8 313.2
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
7.58
8.81
8.04
7.87
5.79
30.51
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0
0
0
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
-0.24
-0.29
-0.21
-0.2
-0.2
-0.89
EBIT per share
-0.54
-0.35
-0.31
-0.29
-0.29
-1.24
EBITDA per share
-0.5
-0.32
-0.28
-0.26
-0.27
-1.14
Total debt per share
—
—
—
—
—
—
Cash per share
2.45
2.03
1.88
1.81
1.71
7.44
Net current asset value per share
2.57
2.1
1.94
1.86
1.76
7.66
Tangible book value per share
2.8
2.44
2.21
1.97
1.74
8.35
Working capital per share
2.23
1.86
1.7
1.62
1.45
6.64
Book value per share
2.8
2.44
2.21
1.97
1.74
8.35
Notícias
Mizuho reitera classificação das ações da Fate Therapeutics com avanço nos ensaios
Fate Therapeutics na Leerink Global Healthcare Conference: mudança estratégica de foco
Fate Therapeutics at Leerink Global Healthcare Conference: Strategic Shift in Focus
Baird mantém classificação neutra para Fate Therapeutics após progresso em ensaios clínicos
Baird reiterates Fate Therapeutics stock rating on trial progress
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Lucro da Fate Therapeutics superou projeções; receita supera estimativas
Fate Therapeutics earnings beat, revenue topped estimates
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Lucro da Fate Therapeutics superou projeções por $0,03; receita supera estimativas
Fate Therapeutics earnings beat by $0.03, revenue topped estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates